Biotech has been one of the worst-performing industry groups this cycle. Investors have got used to it as these stocks have been dead money for much of the past decade.
Every day, we sift through the filings to spot where the real conviction lies – cutting through the noise to highlight the most meaningful insider moves.
Last week was packed with market earnings reactions. We saw double beats, historic selloffs, and a $100B surge in market cap. Investors were forced to separate strength from weakness. And with several...
